You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Compatibility between Brain-Computer Interface and High-Efficiency Augmentative and Alternative Communication Systems

    SBC: Prentke Romich Company            Topic: NIDCD

    Compatibility Between Brain Computer Interface and High Efficiency Augmentative and Alternative Communication SystemsPhase II ABSTRACTBrain computer interfacesBCIenable text production for people who cannot movebut have only simple communication interfaces and are not widely usedAugmentative and alternative communicationAACsystems are widely used and give efficient and precise communicationbut req ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.

    SBC: BIOMIMETIX JV LLC            Topic: 102

    Ischemic stroke is a leading cause of death and disability in the United StatesThis often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolismPatients who present withinhours of symptom onset are eligible for thrombolysis with tissue plasminogen activatortPAThis serves andltof victimsRecentlymajor advance has been made with proven efficacy from endovascular mechani ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: Bertec Corporation            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    GlioblastomaGBMis the most lethal form of adult brain cancers with a median survival of andltmonths despite aggressive standard chemoradiationGBM are formed by GBM stem like cellsGSCsa major contributor to tumor recurrence and a natural focus for therapeutic developmentThere are two main reasons responsible for treatment failurehigh intraand inter tumor cellular and molecular heterogeneity with mu ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: Cetya Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY Thehemoglobinopathies are prevalent genetic blood diseases with few treatment optionsIt is estimate thatof the worldandapos s population carries an abnormal hemoglobin gene withinfants born annually with a severe life threatening hemoglobinopathyDrug mediated induction of normalbut developmentally silencedfetal hemoglobinHbFexpression reduces anemia and ameliorates clinical severit ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Extending WAAVES+: An animal and environment-agnostic, automated USV scoring platform for high-throughput social, behavioral, and neuropharmacological studies

    SBC: Cornerstone Research Group, Incorporated            Topic: 101

    Project SummaryUltrasonic vocalizationsUSVsare known to reflect emotional processingbrain neurochemistry and brain functionkey observations in animal model studiesCollecting and processing USV data is time intensivemanualand costlyMost importantlyit limits researchersability to employ fully effectiveand nuanced experimental designsand is a barrier to entry for other researchersAutomated tabulation ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder

    SBC: Virogenomics BioDevelopment Inc            Topic: R41

    Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Evolution of an Adaptable Prosthetic Foot Design for Normalization of Biomechanics During Community Participation

    SBC: OHIO WILLOW WOOD COMPANY, THE            Topic: NICHD

    Evolution of an Adaptable Prosthetic Foot Design for Normalization ofBiomechanics During Community Participation Summary AbstractThe vision of this project is to improve the functional physical mobility of people with lower extremity amputations especially on uneven groundside slopes or when foot placement varies from side to sidePeople with amputations will be enabled to confidently participate i ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome

    SBC: Longeveron LLC            Topic: NIA

    The metabolic syndromeMetSis a cluster of factors that increases the risks for cardiovascular diseasetypediabetes mellitusand mortalityand currently affects andgtof US adultsMetS is associated with endothelial dysfunctiondecreased circulating endothelial progenitor cellsEPCsand a pro inflammatory stateWe have made the exciting discovery that therapy with allogeneic mesenchymal stem cellsMSCsrestor ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Stem Cells for Treating Acute Stroke

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: 999

    ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government